UNSPSC 51334413: Prideperone

This classification denotes an anxiolytic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 78W508SA0Q. European Medicines Agency schedules Prideperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10036MIG. Prideperone generally arises in the molecular formula C23H24FN3O3. The term PRIDEPERONE is an International Non-Proprietary Name or INN. PRIDEPERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule prideperone under HS 29333999 and SITC 51574. As of Q4 2014, PRIDEPERONE remains the US FDA Preferred Term for this commodity. Prideperone bears US NLM identifiers UMLS ID C2347673 and NCI Concept Code C73288. SMILES: FC1CCC(C(=O)C2CCN(CC2)CCNC(=O)C2C(OC)CCC(C2)C#N)CC1.

UNSPSC 51334413 Prideperone is a Commodity code under which state and local governments procure pharmaceutical products, including naloxone, generic multi-source pharmaceuticals, over-the-counter medications, and related health system supplies to support community health initiatives, pharmacy benefit programs, and emergency response capabilities. The scope encompasses both direct product procurement and participation in cooperative purchasing agreements that aggregate demand across multiple jurisdictions and government entities. State and local issuing bodies soliciting under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances that coordinate procurement for participating state agencies and local government facilities.

Recent activity shows procurement spread across Florida, Texas, and Minnesota through a mix of issuing bodies and purchase mechanisms. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, targeting vendor capabilities for self-insured employer and government health plan contracting. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities including Oregon, with proposals due March 26, 2026 and awarded vendors to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) effective July 1, 2026.